Kiniksa Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Kiniksa Pharmaceuticals
KNSA Stock  USD 19.66  0.22  1.11%   
Kiniksa Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Kiniksa Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kiniksa Pharmaceuticals financial statements helps investors assess Kiniksa Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Kiniksa Pharmaceuticals' valuation are summarized below:
Gross Profit
234.4 M
Profit Margin
(0.02)
Market Capitalization
1.4 B
Enterprise Value Revenue
3.182
Revenue
384.1 M
We have found one hundred twenty available fundamental ratios for Kiniksa Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kiniksa Pharmaceuticals last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of February 1, 2025, Market Cap is expected to decline to about 686 M. In addition to that, Enterprise Value is expected to decline to about 597.1 M

Kiniksa Pharmaceuticals Total Revenue

326.34 Million

Check Kiniksa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiniksa Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 1.6 M or Depreciation And Amortization of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0 or PTB Ratio of 2.65. Kiniksa financial statements analysis is a perfect complement when working with Kiniksa Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiniksa Pharmaceuticals Correlation against competitors.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.

Kiniksa Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets309.2 M605.3 M218.9 M
Slightly volatile
Other Current Liabilities63.8 M60.8 M21 M
Slightly volatile
Total Current Liabilities38.2 M73.2 M25.2 M
Slightly volatile
Property Plant And Equipment Net7.4 M14.6 M4.8 M
Slightly volatile
Accounts Payable5 M9.5 M3.3 M
Slightly volatile
Cash126.9 M124.1 M94.4 M
Slightly volatile
Non Current Assets Total301.9 M287.5 M70.7 M
Slightly volatile
Non Currrent Assets Other903.5 K951 K1.5 M
Slightly volatile
Other Assets1.091.1513.7 M
Pretty Stable
Cash And Short Term Investments212.4 M237.3 M145.7 M
Slightly volatile
Common Stock Total Equity13.4 K21.9 K9.1 K
Slightly volatile
Common Stock Shares Outstanding57.9 M82.7 M47.3 M
Slightly volatile
Short Term Investments117.9 M113.2 M68.1 M
Slightly volatile
Non Current Liabilities Total25 M21.4 M48.5 M
Slightly volatile
Capital Surpluse571.2 M1 B382.4 M
Slightly volatile
Other Current Assets21.2 M20.2 M6.9 M
Slightly volatile
Total Liabilities52.8 M78.7 M72 M
Slightly volatile
Deferred Long Term Liabilities522.8 K497.9 K231.2 K
Slightly volatile
Property Plant And Equipment Gross24.7 M23.5 M7.7 M
Slightly volatile
Preferred Stock Total Equity109.8 M137.7 M102.8 M
Slightly volatile
Total Current Assets234.8 M317.7 M162.4 M
Slightly volatile
Common Stock14.4 K23 K9.3 K
Slightly volatile
Property Plant Equipment3.7 M1.9 M1.9 M
Slightly volatile
Net Working Capital216.3 M244.5 M127.8 M
Slightly volatile
Other Liabilities16.7 M15.9 M3.9 M
Slightly volatile
Capital Stock18.9 K23 K15.6 K
Slightly volatile
Non Current Liabilities Other2 M2.1 M2 M
Slightly volatile
Deferred Long Term Asset Charges1.3 M1.5 M1.6 M
Slightly volatile
Short and Long Term Debt Total7.5 M14.1 M5 M
Slightly volatile
Current Deferred Revenue262.5 K276.3 K17.8 M
Slightly volatile
Capital Lease Obligations7.5 M14.1 M5 M
Slightly volatile
Short Term Debt4.7 M2.6 M2.8 M
Slightly volatile
Intangible Assets14.6 M15.5 M18.5 M
Slightly volatile

Kiniksa Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income1.6 M1.1 M1.1 M
Slightly volatile
Interest Income1.6 M1.1 M1.1 M
Slightly volatile
Depreciation And Amortization1.9 M2.7 M1.2 M
Slightly volatile
Selling General Administrative144.8 M137.9 M46.5 M
Slightly volatile
Other Operating Expenses356.8 M339.8 M129.2 M
Slightly volatile
Research Development89.1 M87.5 M58.1 M
Slightly volatile
Total Operating Expenses153.1 M274.8 M105.3 M
Slightly volatile
Total Other Income Expense Net10.3 M9.8 M2.7 M
Slightly volatile
Reconciled Depreciation1.9 M2.8 M1 M
Slightly volatile
Non Operating Income Net Other2.1 M1.1 M3.5 M
Slightly volatile
Non Recurring668 K751.5 K819.3 K
Slightly volatile

Kiniksa Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation16.5 M31.2 M10.6 M
Slightly volatile
Begin Period Cash Flow84.7 M141.1 M65.9 M
Slightly volatile
Depreciation1.6 M2.7 M1 M
Slightly volatile
Capital Expenditures142 K149.5 K1.9 M
Pretty Stable
Total Cash From Financing Activities1.3 M1.3 M63 M
Very volatile
End Period Cash Flow94.7 M124.1 M77.7 M
Slightly volatile
Change To Liabilities19.2 M18.3 M6.6 M
Slightly volatile
Issuance Of Capital Stock2.9 M3.1 M217.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.975.2316.9224
Slightly volatile
Days Sales Outstanding36.7233.0336.5619
Slightly volatile
Stock Based Compensation To Revenue0.110.120.5176
Slightly volatile
Capex To Depreciation0.06070.06392.0297
Pretty Stable
EV To Sales4.584.8214.5518
Slightly volatile
Inventory Turnover2.382.092.3859
Slightly volatile
Days Of Inventory On Hand138181154
Slightly volatile
Payables Turnover6.486.172.4524
Slightly volatile
Research And Ddevelopement To Revenue0.310.322.0077
Slightly volatile
Capex To Revenue5.0E-46.0E-40.3974
Slightly volatile
Cash Per Share5.413.393.6584
Pretty Stable
Interest Coverage4.75.295.7717
Slightly volatile
Days Payables Outstanding58.1761.243.5 K
Slightly volatile
Income Quality0.841.090.8421
Pretty Stable
Current Ratio9.34.9914.2938
Slightly volatile
Receivables Turnover8.8611.449.9946
Slightly volatile
Graham Number4.554.7910.0188
Slightly volatile
Capex Per Share0.00160.00170.0344
Pretty Stable
Revenue Per Share2.023.471.2041
Slightly volatile
Interest Debt Per Share0.0880.160.0761
Slightly volatile
Debt To Assets0.01480.0210.0139
Slightly volatile
Operating Cycle164207189
Slightly volatile
Days Of Payables Outstanding58.1761.243.5 K
Slightly volatile
Ebt Per Ebit0.810.590.9652
Pretty Stable
Quick Ratio4.214.4313.8763
Slightly volatile
Cash Ratio1.851.9512.2583
Slightly volatile
Days Of Inventory Outstanding138181154
Slightly volatile
Days Of Sales Outstanding36.7233.0336.5619
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.890.9959
Slightly volatile
Fixed Asset Turnover15.2619.218.89
Slightly volatile
Debt Ratio0.01480.0210.0139
Slightly volatile
Price Sales Ratio4.975.2316.9224
Slightly volatile
Asset Turnover0.310.460.2343
Slightly volatile
Gross Profit Margin0.620.710.7547
Slightly volatile

Kiniksa Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap686 M1.1 B777.8 M
Slightly volatile
Enterprise Value597.1 M1 B690.3 M
Slightly volatile

Kiniksa Fundamental Market Drivers

Cash And Short Term Investments206.4 M

Kiniksa Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Kiniksa Pharmaceuticals Financial Statements

Kiniksa Pharmaceuticals stakeholders use historical fundamental indicators, such as Kiniksa Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Kiniksa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kiniksa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Kiniksa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kiniksa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue276.3 K262.5 K
Total Revenue310.8 M326.3 M
Cost Of Revenue65 M68.3 M
Stock Based Compensation To Revenue 0.12  0.11 
Research And Ddevelopement To Revenue 0.32  0.31 
Revenue Per Share 3.47  2.02 
Ebit Per Revenue(0.08)(0.09)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
EBRCentrais Electricas Brasileiras
HEHawaiian Electric Industries
VFCVF Corporation
When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:
How To Invest In Kiniksa
Details
Is Kiniksa Stock a good investment?
Details
What is Kiniksa Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Kiniksa Pharmaceuticals Correlation against competitors.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.5
Earnings Share
(0.12)
Revenue Per Share
5.415
Quarterly Revenue Growth
0.674
Return On Assets
(0.03)
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY